COGENT BIOSCIENCES, INC.

(COGT)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
4.170 USD   +0.72%
05/12Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
AQ
05/10Wedbush Adjusts Price Target for Cogent Biosciences to $17 From $21, Maintains Outperform Rating
MT
05/10COGENT BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Kiq Bio LLC entered into a term sheet agreement to acquire Unum Therapeutics Inc. for $22.7 million in a reverse merger transaction.

07/06/2020 EDT

Kiq Bio LLC entered into a term sheet agreement to acquire Unum Therapeutics Inc. (NasdaqGS:UMRX) for $22.7 million in a reverse merger transaction on June 4, 2020. Kiq Bio LLC acquired Unum Therapeutics Inc. in a reverse merger transaction on July 6, 2020. Under the terms of the merger agreement, at the closing of the merger, Unum issued the security holders of Kiq, 6.24 million shares of the common stock of Unum and 0.04 million shares of series A preferred stock. Immediately following the closing of the merger, the former security holders of Kiq as of immediately prior to the merger owned approximately 60.8% of Unum on a fully-diluted basis and stockholders of Unum as of immediately prior to the merger owned approximately 39.2% of Unum on a fully-diluted basis. Concurrently and in connection with the execution of the merger agreement, former Kiq security holders as of immediately prior to the merger, and the directors and officers of Unum as of immediately following the merger, which collectively own an aggregate of approximately 30.7% of Unum outstanding capital stock, entered into lock-up agreements with Unum and Kiq, pursuant to which each stockholder will be subject to a 90 day lockup on the sale or transfer of shares of common stock held by each such stockholder at the closing of the merger, including those shares received by Kiq security holders in the merger. The management of the combined entity will include Chuck Wilson as President and Chief Executive Officer, Jessica Sachs, as Chief Medical Officer, and John Green, as Chief Financial Officer. In conjunction with the transaction, the Board members of combined entity will include Chris Cain, Karen Ferrante, Peter Harwin, Arlene Morris, Matthew Ros, and Chuck Wilson, President and Chief Executive Officer, Unum Therapeutics. On July 6, 2020, immediately prior to the effective time of the merger, Bruce Booth and Joern Aldag resigned from the Board and any respective committee of the Board of Unum to which they were members. In connection with the closing of the merger, Matthew Ros, Arlene Morris and Peter Harwin were appointed to the audit committee of the Board, and Matthew Ros was appointed the chair of the audit committee. The transaction is subject to the approval of the listing of the additional shares of Utah common stock on Nasdaq having been obtained and the shares of Utah common stock to be issued in merger pursuant to this agreement having been approved for listing on Nasdaq, an acquisition of shares of preferred stock of Unum to be consummated concurrently with the closing pursuant to the securities purchase agreement and Kiq Bio LLC having obtained the required vote of its members. The Board of Directors of Unum unanimously approved the agreement and the related transactions, and the consummation of the transaction was not subject to approval of the stockholders of Unum. The transaction was also approved by the board of Kiq Bio LLC. Kingsley L. Taft, Danielle M. Lauzon, Nicole Daley, and Andrew H. Goodman of Goodwin Procter LLP acted as legal advisors to Unum and Ryan Murr and Chris Trester of Gibson, Dunn & Crutcher LLP acted as legal advisor to Kiq. Ladenburg Thalmann & Co. Inc. acted as financial advisor and fairness opinion provider to Unum. Wedbush Securities Inc. acted as exclusive strategic advisor to Kiq. Pursuant to the engagement letter between Ladenburg and Unum, Ladenburg received a transaction fee of $1,100,000 in cash at the closing of the transaction. Unum has also paid Ladenburg an initial fee of $150,000 and an Opinion fee of $250,000 upon delivery of its Opinion which was credited against the transaction fee. Computershare Trust Company, NA acted as transfer agent to Unum. The Proxy Advisory Group, LLC acted as proxy solicitor to Unam. Kiq Bio LLC completed the acquisition of Unum Therapeutics Inc. (NasdaqGS:UMRX) in a reverse merger transaction on July 6, 2020.


ę S&P Capital IQ 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIKE24 HOLDING AG -4.55% 5.25 Delayed Quote.-65.09%
COGENT BIOSCIENCES, INC. 0.72% 4.17 Delayed Quote.-51.40%
All news about COGENT BIOSCIENCES, INC.
05/12Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annu..
AQ
05/10Wedbush Adjusts Price Target for Cogent Biosciences to $17 From $21, Maintains Outperfo..
MT
05/10COGENT BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/10Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/10Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial ..
AQ
05/09Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation S..
AQ
05/09Cogent Biosciences Files $300 Million Mixed Shelf
MT
05/06Cogent Biosciences Terminates $75 Million At-The-Market Offering Program
MT
05/06COGENT BIOSCIENCES, INC. : Termination of a Material Definitive Agreement (form 8-K)
AQ
05/06Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation S..
AQ
More news
Analyst Recommendations on COGENT BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -130 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,64x
Yield 2022 -
Capitalization 191 M 191 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 77
Free-Float 100,0%
Chart COGENT BIOSCIENCES, INC.
Duration : Period :
Cogent Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COGENT BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,17 $
Average target price 20,00 $
Spread / Average Target 380%
EPS Revisions
Managers and Directors
Andrew R. Robbins President, Chief Executive Officer & Director
John L. Green Chief Financial & Accounting Officer
Peter Harwin Chairman
Jessica Sachs Vice President-Clinical Sciences
Brad Barnett Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
COGENT BIOSCIENCES, INC.-51.40%190
GILEAD SCIENCES, INC.-12.93%79 248
REGENERON PHARMACEUTICALS, INC.4.38%71 927
VERTEX PHARMACEUTICALS14.91%66 967
WUXI APPTEC CO., LTD.-18.77%42 682
BIONTECH SE-38.01%38 834